期刊
CLINICAL AND MOLECULAR HEPATOLOGY
卷 28, 期 1, 页码 91-104出版社
KOREAN ASSOC STUDY LIVER
DOI: 10.3350/cmh.2021.0236
关键词
Hepatitis C virus; Mass screenings; Cost effectiveness; Quality adjusted life years
资金
- Korea Disease Control and Prevention Agency [2020-E510400]
- Research Supporting Program of The Korean Association for the Study of the Liver and The Korean Liver Foundation
This study evaluates the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population. It finds that one-time universal HCV screening is highly cost-effective from both healthcare system and societal perspectives.
Background/Aims: This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives. Methods: A published decision-tree plus Markov model was used to compare the expected costs and quality-adjusted life years (QALY) between one-time universal HCV screening and no screening in the population aged 40-65 years using the National Health Examination (NHE) program. Input parameters were obtained from analyses of the National Health Insurance claims data, Korean HCV cohort data, or from the literature review. The population aged 40-65 years was simulated in a model spanning a lifetime from both the healthcare system and societal perspectives, which included the cost of productivity loss due to HCV-related deaths. The incremental cost-effectiveness ratio (ICER) between universal screening and no screening was estimated. Results: The HCV screening strategy had an ICER of $2,666/QALY and $431/QALY from the healthcare system and societal perspectives, respectively. Both ICERs were far less than the willingness-to-pay threshold of $25,000/QALY, showing that universal screening was highly cost-effective compared to no screening. In various sensitivity analyses, the most influential parameters on cost-effectiveness were the antibodies to HCV (anti-HCV) prevalence, screening costs, and treatment acceptance; however, all ICERs were consistently less than the threshold. If the anti-HCV prevalence was over 0.18%, screening could be cost-effective. Conclusions: One-time universal HCV screening in the Korean population aged 40-65 years using NHE program would be highly cost-effective from both healthcare system and societal perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据